STRUCTURAL GENOMIX INITIATES PHASE II/III TROXATYL TRIAL
Structural GenomiX announced that the first patient has been enrolled in a Phase
II/III clinical trial of Troxatyl, a novel anticancer drug candidate for treatment
of acute myelogenous leukemia (AML). The study, with targeted enrollment of
211 patients at approximately 40 trial centers in the U.S. and Europe, is designed
to establish the safety and effectiveness of Troxatyl in patients with relapsed
or refractory AML.
The patients targeted in this Phase II/III study are those who are in second relapse with duration of second response less than six months, or who were refractory to two previous courses of induction chemotherapy.